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Abstract
The Autism Spectrum Disorders (ASD) represent a clinically heterogeneous set of conditions with strong hereditary
components. Despite substantial efforts to uncover the genetic basis of ASD, the genomic etiology appears complex and a
clear understanding of the molecular mechanisms underlying Autism remains elusive. We hypothesized that focusing
gene interaction networks on ASD-implicated genes that are highly expressed in the developing brain may reveal core
mechanisms that are otherwise obscured by the genomic heterogeneity of the disorder. Here we report an in silico study of
the gene expression profile from ASD-implicated genes in the unaffected developing human brain. By implementing a
biologically relevant approach, we identified a subset of highly expressed ASD-candidate genes from which interactome
networks were derived. Strikingly, immune signaling through NFkB, Tnf, and Jnk was central to ASD networks at multiple
levels of our analysis, and cell-type specific expression suggested glia—in addition to neurons—deserve consideration. This
work provides integrated genomic evidence that ASD-implicated genes may converge on central cytokine signaling
pathways.
Citation: Ziats MN, Rennert OM (2011) Expression Profiling of Autism Candidate Genes during Human Brain Development Implicates Central Immune Signaling
Pathways. PLoS ONE 6(9): e24691. doi:10.1371/journal.pone.0024691
Editor: Ying Xu, University of Georgia, United States of America
Received April 6, 2011; Accepted August 18, 2011; Published September 15, 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by the Intramural Research Program at National Institute of Child Health and Human Development, National Institutes of
Health (NIH). MNZ was also supported by the NIH-University of Cambridge Biomedical Scholars Program and Baylor College of Medicine MSTP. The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ziatsm@mail.nih.gov
Introduction
The Autism Spectrum Disorder is a heterogeneous neurode-
velopmental syndrome defined by impairments in communication,
social interaction, and restricted or stereotyped patterns of
behavior. ASD is the most heritable of the common neuropsychi-
atric conditions with estimates approaching 90% in monozygotic
twins, 10% in dizygotic twins, and recurrence risk in siblings
10–100 times the general population [1,2,3,4]. Moreover,
approximately 10–20% of ASD cases are associated with
recognizable syndromes of known etiology—representing a large
number of rare alleles [5]. With recent advances in comparative
genomic hybridization (CGH), approximately 40% of patients
with a diagnosis of ASD will have a detectable genomic aberration
[6]. However, this genetic etiology is complex and likely involves
gene-gene, gene-environment, and epigenetic interactions, reflect-
ing the overlying broad clinical presentation of ASD. This is
evidenced by the less than 100% penetrance in identical twins, the
discordance in heritability between mono- and dizygotic twins,
and the considerable variability within pedigrees [7,8]. Further-
more, the clinical phenotype and underlying genetics of the
syndromic forms of ASD are extremely varied, and differences in
manifestations of the three core symptoms are observed even
within a specific diagnostic entity. Moreover, ASD shares
considerable clinical and genetic overlap with other neuropsychi-
atric disorders such as schizophrenia and mental retardation [9],
and ASD patients have significantly increased neurologic co-
morbidities like hypotonia, tics, and epilepsy [10]. In fact, many of
the same gene mutations have been found to predispose to more
than one of these neurodevelopmental disorders [11,12].
Consequently, the approximately 60% of non-syndromic ASD
cases without an identifiable structural variation (here defined as
‘‘intrinsic’’ Autism) represent a broad clinical spectrum with strong
genetic underpinnings that have proven exceedingly difficult to
define. Much work has attempted to elucidate the molecular
genetics underlying intrinsic Autism, with many linkage, function-
al, and genome-wide association studies (GWAS) having implicat-
ed more than 200 loci to date [13,14,15]. Additionally, copy
number variation (CNV) and cytogenetic analysis have further
identified many chromosomal hot spots in ASD [16,17]. It is
apparent from these studies that many different loci, each with a
presumably unique yet subtle contribution to neurodevelopment,
underlie the phenotype of ASD. These observations have
prompted a shift in the paradigm of ASD genetics away from a
common disease/common variant model, to one that recognizes
the contribution of rare variants [5,9]. Because of this great clinical
and genetic heterogeneity, attempts to identify a common
molecular pathology for ASD have remained elusive, and as a
result, diagnosis and treatment are non-specific and suboptimal.
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genetic and molecular levels, both human and animal studies have
begun to demonstrate that disruption of synaptogenesis and
improper connectivity of local and distant brain networks likely
underlie the cellular pathophysiology responsible for the broad
ASD phenotype [18,19]. Multiple different brain regions have
been implicated in both post-mortem and neuroimaging studies,
notably the prefrontal and temporal cortices, and the cerebellum
[20]. Histological analysis has revealed increased cell densities,
changes in synaptic spine morphology, mini-columnar disorgani-
zation, and glial activation [21]. Despite these observations, the
mechanism(s) responsible for this ‘‘disconnection’’ phenotype
remains obscure, as a complex interplay between diverse cell
types and functions modulate the developing network architecture
in both a temporal and spatially regulated manner [22,23,24]. A
main question in ASD research has become, then, how to
reconcile the genetic and phenotypic heterogeneity with the
apparent synaptic network abnormalities underlying the broad
ASD phenotype.
A proposed unifying explanation for this dichotomy posits that
differences in gene expression in the developing brain could
explain how many genes, each with a different contribution to
proper formation of brain circuitry, could result in a single
disorder with neural network dysfunction at its core [25,26]. This
model is underscored by the prototypical Autism Spectrum
Disorder, Rett Syndrome, in which mutations in the Mecp2 gene
result in global dysregulation of the transcriptome [27]. Moreover,
it has been shown that mutations in Mecp2—a transcriptional
repressor—result in aberrant expression at many ASD-implicated
loci [28]. To investigate this model, however, requires gene
expression profiling of ASD-candidate genes in developing human
brain tissue. To date, a number of studies have investigated gene
expression in ASD (for review see [29]), with three examining
ASD brain tissue on a genome-wide scale [30,31,32]. However, no
study explicitly describes the transcriptional profile of ASD-
implicated genes, and by necessity, all were limited in develop-
mental time points and brain regions investigated.
To investigate more thoroughly the notion that differences in
expression of ASD-implicated genes underlies the complex
genomics of the disorder, we hypothesized that focusing gene
interaction networks on ASD-implicated genes with high expres-
sion in the developing brain may reveal core mechanisms that are
otherwise obscured by the heterogeneity of all implicated loci. To
do this, we mined the NIMH Transcriptional Atlas of Human
Brain Development [33] for all genes implicated in ASD that are
included in the database AutDB [34]. The NIMH Atlas contains
next-generation RNA sequencing data from 16 normal human
brain regions, and spans 21 weeks gestation through 40 years of
age. We devised a biologically-driven computational approach to
analyze differential expression across regions and development,
and assessed cell-type specific expression using the Human Protein
Atlas [35]. We discovered distinct molecular interaction networks
using an enriched set of highly expressed genes, which implicated
canonical immune signaling pathways at multiple levels of analysis
as central to ASD.
Results
Evaluating Differential Expression in NIMH
Transcriptional Atlas of Human Brain Development
The NIMH Atlas reports the normalized reads per kilobase of
exon model per million mapped reads (RPKM) units [36];
whereas primary RNA-seq analysis pipelines have the advantage
of using raw read counts for statistical evaluation of differential
gene expression. Thus, we first established a qualitative differential
expression methodology that could directly interpret RPKM
values with consistency and validity across different brain regions
and time points. This allowed us to identify a subset of genes that
were highly expressed directly from RPKM data.
To achieve this, we examined the expression profile of the top
15 genes determined by Hsiao et al as constantly expressed from 59
different whole-genome microarrays in 19 different tissue types
[37]. For 11 of the 15 genes there was consistency in expression
across developmental time points and in different brain regions
(Fig. S1). To validate our approach further, we selected at random
10 canonical housekeeping genes representing 10 different cellular
processes [38]. We observed consistent expression for all 10 of
these genes across brain regions and time points (Fig. S2). This
resulted in a total of 21 housekeeping genes with constant
expression (11 from Hsiao et al and 10 canonical), which we used
to define normal biological variance in the NIMH Atlas. To
stratify the NIMH Atlas data, we grouped expression values into
quintiles (,20 RPKM, 20–40 RPKM, 40–60 RPKM, 60–80
RPKM and .100 RPKM), as previously reported for microarray
expression data in brain [39]. Of the 21 constantly expressed
housekeeping genes, we noted they all vary within three
consecutive quintile tiers. Based on these results, we concluded
that genes crossing more than three tiers were significantly
differentially expressed, as opposed to exhibiting normal biological
variation. This initial approach demonstrated that reported
RPKM values could be used qualitatively to assess differences in
gene expression levels.
Notably, expression values at the 6 mo time point were
considerably lower for almost all genes and brain regions. This
may be a function of lowered CNS transcriptional activity at this
age, however a systematic error in sequencing is also likely. Since
we were interested in highly expressed genes, we were not
concerned this would introduce false-positive results into our
subsequent analysis.
Expression of Brain-specific markers
We analyzed genes of brain-specific markers (adhesion/elastic/
filament proteins) with intermediate expression to further validate
our method and gain insight into cell-type specific expression across
brain regions and during different developmental time points. As
seen in Figure S3, Keratin and Desmin—markers of epithelia and
muscle, respectively—were not expressed as expected. Neurofila-
ment (Nefl), a neuron-specific maker, showed high expression in
most brain regions after 24 weeks gestation (wg). Notably,
expression of Nefl was significantly lower in the cerebellum, which
is consistent with our observation at the protein level (see below).
Expression of Glial Fibrillary Acid Protein (Gfap), an astrocyte-
specific intermediate filament, also showed high expression in all
brain regions beginning at the fourth postnatal month, although
markedly later in development than Nefl. Interestingly, Vimentin, a
marker of mesenchyme-derived cells, exhibits a differential
expression pattern with very high expression in the early developing
brain (24 wg–4 mo). This may be a reflection of invading microglia,
which are of mesenchymal origin and known to enter the
developing brain during early embryogenesis [40], and/or it may
relate to the laying down of the vasculature and extracellular matrix
early in development.
Expression Profile of genes implicated in ASD, Epilepsy,
and Schizophrenia
We parsed the NIMH database for all genes implicated in
Autism that are described in the database AutDB (Table S1
and Methods). To strengthen our approach and investigate the
Autism Candidate Genes Implicate Immune Signaling
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Epilepsy with ASD, we also investigated all genes implicated in
these disorders, which are cataloged in the databases SZGene and
CarpeDB, respectively (Table S1). Non-redundant, protein-coding
loci that were present in the NIMH atlas were included in this
study, as summarized in Figure 1. Only 11 genes are shared by all
three disorders. Gene ontology (GO) enrichment analysis of these
11 overlapping genes as opposed to all genes implicated in all three
disease databases yielded many significant pathways mainly
involved in the response to external stimuli and GABA metabolism
(Table 1).
We constructed expression heatmaps for all genes by brain
region and time-point by assigning each RPKM expression value
to one of five quintiles, and then grouping genes into five
expression tiers (see Methods; Tables S2, S3, S4). Strikingly, for
each of the three disease sets more than 55% of genes were never
expressed above 20 RPKM, with the majority of these less than 5
RPKM (Table 2). For ASD candidate genes, greater than 70%
were not expressed highly in each brain region. In each region, a
large percentage of ASD-implicated genes had no detectable
transcription (,1 RPKM). For instance, in the hippocampus 46
out of 219 (21%) ASD-implicated genes had no detectable
transcripts. Similar proportions were not detected in the
cerebellum (52/219 or 24%) or dorsolateral prefrontal cortex
(40/219 or 18%). While it is possible that these loci still have
functional roles in ASD genomics via cis-regulation or other
mechanisms, we reasoned that their inclusion in protein-
interaction networks might obscure more prominent molecular
mechanisms underlying ASD.
It is of note that the cerebellum and frontal cortex contained the
greatest number of highly expressed ‘‘Autism genes’’ and the
temporal cortex had the greatest number of ‘‘Epilepsy genes,’’
whereas Schizophrenia gene expression distributed more evenly
throughout the brain. While much work in Autism has focused on
thehippocampusasa potentialepicenterofpathology,wefound the
developing hippocampus had the fewest ASD candidate genes
expressed at high levels, and none were specific for the hippo-
campus. Conversely, the cerebellum contained a unique set of six
Autism candidate genes that were not highly expressed in any other
brain region. These included the canonical neurodevelopmental
genes Nlgn3 and Reln, two cell adhesion molecules, and 7-
dehydrocholesterol reductase. This is intriguing since multiple
imaging studies have implicated the cerebellum in the pathogenesis
of Autism [41]. The NIMH Atlas parcels the frontal cortex into four
subregions, yet the expression profile of ASD genes between them
was similar. Only one gene (Gabrb3) was specific to the frontal
cortex, and it was only present at high levels in the ventrolateral
prefrontal cortex. Interestingly, this gene lies in the 15q11–13
imprinted region implicated in Prader-Willi and Anglemen
Syndromes, and is one of the most reproducible loci identified in
ASD genome-wide association studies [42].
For the remainder of our analysis, we focused on genes in the top
three expression tiers (at least one time-point .60 RPKM) as genes
that are significantly highly expressed as compared to all ASD-
implicated genes (based on our ‘‘housekeeping gene’’ results). This
yielded 32 genes for Autism, 42 for Epilepsy and 212 for
Schizophrenia (Fig. 2). Autism shared eight highly expressed genes
with Schizophrenia, and only two with Epilepsy (Dcx and Cnr1). GO
Figure 1. Summary of all genes analyzed from AutDB, CarpeDB and SZGene. Number of genes and genes shared between disorders
indicated.
doi:10.1371/journal.pone.0024691.g001
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pathways. There was only one gene—Cannabinoid Receptor 1
(Cnr1)—implicated in all three disorders that is highlyexpressed in the
developing brain. Cnr1 expression is high mainly during gestation,
and is most pronounced in the cerebellum and amygdala (Fig. S4).
Nine Autism genes were highly expressed in all brain regions
examined. These nine genes (Fabp7, Gnas, Gpx1, Hnrnph2, Hras, Pdzd4,
Rpl10, Sez6l2,a n dTspan7) had considerably higher expression than
all other ASD genes (over 500 RPKM in many instances, Fig. S5).
Their temporal expression profiles were mostly constant across
developmental stages, except for Fabp7,w h i c he x h i b i t e dd r a s t i c
differential expression. Fabp7 was expressed much higher than the
other eight genes during almost all time-points, but was highest
during the two gestational time points. Interestingly, Fabp7 (Fatty acid
binding protein 7) is known to interact with Notch in radial glia during
development [43], and we subsequently found it to only be expressed
in glia (see below). The temporal expression of the other 32 highly
expressed genes varied considerably, but was biased toward high
expression in the early time points analyzed (Table S5).
Gene ontology enrichment of the 32 highly expressed Autism
genes revealed four new GO categories representing two
significant processes—immune system regulation and apoptosis
(Table 3). GO enrichment of the highly expressed Schizophrenia
genes yielded a much different set of processes, mostly implicating
cellular morphogenesis, but none involving the immune response
(Table 4). The epilepsy dataset did not enrich for any significant
functions when considering those genes that were highly
expressed. This suggests that ASD-implicated genes with no or
low expression in the developing brain may obscure functional
pathway analysis, which otherwise implicates cytokine signaling.
Network Analysis
Next, we set out to determine if the genes we identified as being
highly expressed in the developing brain implicate different
functional networks as compared to all genes associated with
these diseases. We utilized integrated gene-network analysis using
the curated Ingenuity Pathway Analysis (IPA) database. Initially
we searched for canonical pathways for each disorder, comparing
the highly expressed gene sets to all disease-associated genes
(Tables 5, 6, 7). This analysis implicated many new canonical
pathways from the set of highly expressed genes not seen in the full
dataset analysis. For Autism, this included corticotrophin releasing
hormone signaling, g-protein and phospholipase C signaling, and
neutrophil cytokine signaling. The new pathways implicated in
Schizophrenia included synaptic long-term potentiation and axon
guidance signaling, and in Epilepsy semaphorin signaling and the
splicesome cycle. Interestingly, there are no canonical pathways
shared between the three disorders when the entire set of imp-
licated genes is considered, but analysis of the highly expressed sets
implicates Reelin Signaling in Neurons as common to all three
disorders. Further investigation of this pathway (Fig. S6) shows
almost all molecules are implicated in at least one of these three
neurodevelopmental disorders.
Unbiased gene-network analysis was then constructed in IPA, to
identify connectivity networks derived from the enriched gene set
Table 1. GO enrichment analysis of the 11 genes shared by
Autism, Schizophrenia, and Epilepsy.
GO Term Description P-value
GO:0042220 response to cocaine 1.11E-05
GO:0014073 response to tropane 1.11E-05
GO:0014070 response to organic cyclic compound 6.99E-05
GO:0009450 gamma-aminobutyric acid catabolic process 7.68E-05
GO:0051259 protein oligomerization 1.22E-04
GO:0043279 response to alkaloid 1.75E-04
GO:0009605 response to external stimulus 1.85E-04
GO:0051260 protein homooligomerization 1.99E-04
GO:0009448 gamma-aminobutyric acid metabolic process 2.29E-04
GO:0032103 positive regulation of response to external
stimulus
6.05E-04
GO:0010042 response to manganese ion 7.57E-04
GO:0042135 neurotransmitter catabolic process 7.57E-04
GO:0031622 positive regulation of fever generation 7.57E-04
GO:0031620 regulation of fever generation 7.57E-04
GO:0031650 regulation of heat generation 7.57E-04
GO:0031652 positive regulation of heat generation 7.57E-04
GO:0009607 response to biotic stimulus 8.35E-04
doi:10.1371/journal.pone.0024691.t001
Table 2. Summary of differential gene expression across all brain regions.
Region % of genes less than 20 RPKM % of genes in Top 3 Tiers
Autism Epilepsy Schizophrenia Autism Epilepsy Schizophrenia
DLPC 71% 59% 67% 7% 18% 16%
VLPC 73% 59% 67% 7% 17% 16%
MPC 77% 59% 69% 7% 18% 15%
OFC 74% 58% 69% 6% 20% 16%
Motor 74% 61% 68% 6% 18% 16%
PS Temp 74% 57% 69% 6% 19% 16%
IL Temp 73% 59% 68% 8% 21% 15%
Hippo 79% 63% 70% 5% 15% 14%
Amygdala 74% 56% 66% 5% 19% 16%
Striatum 73% 58% 67% 6% 19% 16%
Cerebellum 77% 62% 67% 8% 14% 15%
doi:10.1371/journal.pone.0024691.t002
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Overlaying derived networks based on connectivity revealed that
the two networks constructed from the highly expressed ASD
genes are central to all networks obtained from all ASD-associated
genes (Figure 3). In the first central network (Figure 4), NFkB, Jnk,
and Mapk are hubs. Network 2 from the highly enriched set also
contains NFkB as a hub, in addition to Tnf, TgfB1 and Myc
(Figure 5). Taken together, these enriched networks, which are the
most inter-connected of all ASD-derived networks, have at their
core fundamental cytokine signaling molecules not previously
implicated as ASD susceptibility loci. These may serve as potential
final common pathways through which the heterogeneous ASD-
implicated genes ultimately converge. Moreover, this represents a
third, independent level of analysis whereby the highly expressed
ASD genes implicate immune signaling pathways that are not
apparent when the full set of ASD-associated genes is considered.
Similar analysis comparing ASD-associated gene networks specific
to brain regions did not result in a significant clustering by region, nor
were there central network nodes (Fig. S7). Considering only genes
expressed highly during gestational time points, we did not observe any
new pathways or networks not already implicated using all time points.
Gene-network analysis of the Epilepsy and Schizophrenia gene sets did
not result in centrality of the highly expressed networks as we observed
in ASD (Figures S8 and S9), perhaps reflecting the less heterogeneous
nature of these disorders.
Correlating Gene Transcription with Cell-type Specific
Protein Expression
Next, we were interested in correlating our ASD gene
transcriptome results with protein expression levels in a cell-type
specific manner. To do so, we mined the Human Protein Atlas
database for the 32 highly expressed Autism genes (see Methods,
Figure 2. Summary of the subset of highly expressed genes identified from our analysis.
doi:10.1371/journal.pone.0024691.g002
Table 3. GO enrichment analysis of highly expressed Autism
genes.
GO Term Description P-value
GO:0002682 regulation of immune system process 0.0001
GO:0006915 apoptosis 0.0009
GO:0012501 programmed cell death 0.0009
GO:0031347 regulation of defense response 0.0009
doi:10.1371/journal.pone.0024691.t003
Table 4. GO enrichment analysis of highly expressed
Schizophrenia genes.
GO Term Description P-value
GO:0048812 neuron projection morphogenesis 0.00001
GO:0032990 cell part morphogenesis 0.00002
GO:0048858 cell projection morphogenesis 0.00002
GO:0032989 cellular component morphogenesis 0.00007
GO:0007409 axonogenesis 0.00007
GO:0090066 regulation of anatomical structure size 0.00008
GO:0051129 negative regulation of cellular component
organization
0.00063
GO:0032535 regulation of cellular component size 0.00065
GO:0010721 negative regulation of cell development 0.00083
GO:0007417 central nervous system development 0.00083
GO:0030030 cell projection organization 0.00084
GO:0031344 regulation of cell projection organization 0.00096
doi:10.1371/journal.pone.0024691.t004
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genes are mainly detected in glia not neurons, and/or in specific layers of the
cerebellum. A similar proportion of genes exhibit neuron-specific
protein expression. We also observed that Gnas, a complex locus
known to be imprinted and express antisense and non-coding
transcripts [44], does not appear to make detectable protein in the
CNS, yet is one of the 9 most highly expressed ASD transcripts in
the NIMH atlas. Fabp7, which we noted was the most highly
expressed ASD-associated gene, is only detected in glia. Moreover,
Cnr1—the one highly expressed gene shared by all three
disorders—is most highly expressed in glial cells and the molecular
layer of the cerebellum. These results suggest future investigation
of cell-type specific expression in ASD will be an important
undertaking, and consideration of non-coding RNAs in ASD
pathogenesis is warranted as well.
Analysis of ASD Transcriptome Data
Lastly, we were interested in considering our findings in the
context of the major three published transcriptomics studies on
ASD brain tissue [30,31,32]. Two of these have implicated
immune alterations in ASD brain as compared to controls. We
examined the results of all three studies to determine how many of
the dysregulated genes reported were ASD implicated genes
present in AutDB. Surprisingly, in each study only ,5% of genes
that are significantly different between ASD and control brains
were previously implicated in ASD (Table 9). This underscores the
importance of our findings on ASD-implicated genes, as both our
approach and whole-transcriptomics studies implicate immune
signaling pathways, even though most ASD-implicated genes we
profiled are not dysregulated in ASD brain tissue.
Discussion
In an attempt to integrate the genomic heterogeneity underlying
the complex etiologies of common neurodevelopmental disorders,
we report here the analysis of expression from all implicated genes
in Autism, Schizophrenia, and Epilepsy using next-generation
transcriptome sequencing in the developing human brain. Sakai
et al recently constructed a protein interactome network using a
Table 5. Canonical Pathways implicated in ASD when considering all genes versus highly expressed genes.
Canonical Pathways Derived from All
AutDB Genes P-Value
Canonical Pathways Derived from 32 Highly
Expressed ASD Genes P-Value
Serotonin Receptor Signaling 4.4E-08 Corticotropin Releasing Hormone Signaling 4.5E-05
Reelin Signaling in Neurons** 5.4E-06 G-Protein Coupled Receptor Signaling** 2.5E-04
HER-2 Signaling in Breast Cancer 5.0E-05 Role of NFAT in Cardiac Hypertrophy 3.1E-04
cAMP-mediated Signaling** 6.9E-05 Reelin Signaling in Neurons**# 3.7E-04
G-Protein Coupled Receptor Signaling** 7.6E-05 Factors Promoting Cardiogenesis in Vertebrates 5.0E-04
Virus Entry via Endocytic Pathways** 1.7E-04 a-Adrenergic Signaling 5.1E-04
Macropinocytosis Signaling 1.8E-04 cAMP-mediated Signaling** 5.1E-04
Axonal Guidance Signaling 2.2E-04 Virus Entry via Endocytic Pathways** 5.5E-04
PTEN Signaling 3.8E-04 G Beta Gamma Signaling 5.9E-04
GABA Receptor Signaling 4.3E-04 Phospholipase C Signaling 7.2E-04
Glioblastoma Multiforme Signaling 5.9E-04 Cholecystokinin/Gastrin-mediated Signaling 7.8E-04
PI3K/AKT Signaling 9.1E-04 fMLP Signaling in Neutrophils 9.5E-04
**indicates the pathway was implicated in both sets. #indicates the pathway was common to all three disorders.
doi:10.1371/journal.pone.0024691.t005
Table 6. Canonical Pathways implicated in Schizophrenia when considering all genes versus highly expressed genes.
Canonical Pathways Derived from All
Schizophrenia Genes P-Value
Canonical Pathways Derived from 212 Highly
Expressed Schizophrenia Genes P-Value
Glutamate Receptor Signaling** 1.0E-32 Glutamate Receptor Signaling** 1.3E-12
Amyotrophic Lateral Sclerosis Signaling** 4.0E-23 Reelin Signaling in Neurons**# 4.4E-09
Neuropathic Pain Signaling In Dorsal Horn Neurons 7.9E-22 cAMP-mediated Signaling 1.5E-08
CREB Signaling in Neurons** 1.0E-21 14-3-3-mediated Signaling 4.3E-08
Role of Macrophages, Fibroblasts and
Endothelial Cells in Rheumatoid Arthritis
1.3E-20 Axonal Guidance Signaling 6.6E-08
Role of Osteoblasts, Osteoclasts and
Chondrocytes in Rheumatoid Arthritis
1.3E-19 p70S6K Signaling 8.7E-08
G-Protein Coupled Receptor Signaling 4.0E-18 CREB Signaling in Neurons** 9.1E-08
Human Embryonic Stem Cell Pluripotency 1.3E-17 Synaptic Long Term Potentiation 1.9E-07
Serotonin Receptor Signaling 5.0E-17 Myc Mediated Apoptosis Signaling 1.1E-06
Glucocorticoid Receptor Signaling 7.9E-17 Amyotrophic Lateral Sclerosis Signaling** 1.1E-06
**indicates the pathway was implicated in both sets. #indicates the pathway was common to all three disorders.
doi:10.1371/journal.pone.0024691.t006
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but to our knowledge, no study has yet attempted to derive
molecular pathways underlying ASD by investigating as large of a
set of ASD candidate genes.
To do so, we first described gene ontology, canonical pathways,
and interactome networks for all genes implicated in ASD that are
cataloged in the database AutDB. Then, based on the argument
that differential expression of ASD-implicated genes may underlie
Table 7. Canonical Pathways implicated in Epilepsy when considering all genes versus highly expressed genes.
Canonical Pathways Derived from All Epilepsy
Genes P-Value
Canonical Pathways Derived from 42 Highly
Expressed Epilepsy Genes P-Value
GABA Receptor Signaling** 4.7E-09 Reelin Signaling in Neurons**# 1.3E-06
Neuropathic Pain Signaling In Dorsal Horn Neurons 2.1E-06 GABA Receptor Signaling** 2.8E-04
Reelin Signaling in Neurons** 2.6E-05 Semaphorin Signaling in Neurons 7.1E-03
b-alanine Metabolism 2.2E-04 Spliceosomal Cycle 7.2E-03
Glutamate Receptor Signaling** 7.4E-04 Glutamate Receptor Signaling** 1.1E-02
Calcium Signaling 8.5E-04
Cellular Effects of Sildenafil (Viagra) 1.1E-03
Butanoate Metabolism 2.7E-03
Hepatic Cholestasis 5.5E-03
Glutamate Metabolism 6.0E-03
**indicates the pathway was implicated in both sets. #indicates the pathway was common to all three disorders.
doi:10.1371/journal.pone.0024691.t007
Figure 3. Overlapping gene-networks in ASD. Networks 1 and 2 (yellow border) were derived from the highly expressed ASD gene set. All other
networks were derived from the set of all ASD-implicated genes. Orphaned networks (no edges) were excluded. Edge values represent number of
interactions between networks.
doi:10.1371/journal.pone.0024691.g003
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relevant methodology to extract a subset of highly expressed ASD-
implicated genes from the NIMH Transcriptional Atlas of Human
Brain Development. We found that interactome analysis placed
the two networks derived from highly expressed ASD candidate
genes at the center of all ASD gene networks. Closer inspection of
these networks revealed NFkB, Jnk, MapK, TNF, TGF-B, and
Myc as central hubs. These central networks were supported by
evidence at two other levels of our analysis (Gene ontology and
canonical pathways). Taken together, our findings integrate a large
set of genes implicated in ASD and suggest that they may converge
onto classical cytokine signaling pathways. While other transcrip-
tomics studies on ASD tissue have implicated immune system
signaling in ASD pathogenesis, our findings suggest that the ASD-
implicated genes themselves may also be related to these functions.
Interestingly, there is also mounting evidence at the cellular and
tissue levels that more in depth investigation of an immune
component is warranted in ASD [46]. For instance, multiple
studies have demonstrated altered cytokine profiles in ASD
patients [47,48], and altered TGF-B concentration in serum and
CSF correlates with disease severity [49]. Others have described
various autoimmune phenomena including autoantibodies to
neural antigens and maternal-fetal cross-reactive neural antibodies
[50]. There is also indication of altered innate cellular immunity in
ASD, such as differences in gene expression and altered response
to immunostimlulatory ligands in both natural killer and
monocytic cells from ASD patients [51,52]. Post-mortem brain
tissue from ASD patients shows increased microglial density in
grey matter, an activated morphology, and secretion of a cytokine
profile consistent with a pro-inflammatory state, most prominent
in the cerebellum [53,54]. Moreover, microglia from MeCP2- null
mice—a model of the Autism Spectrum Disorder Rett Syn-
drome—produce a conditioned media that damages synaptic
connectivity via a glutamate-excitotoxicity mechanism [55]. While
Figure 4. Network 1 derived from the ASD highly expressed gene set. Orange genes are those present in AutDB that are highly expressed.
doi:10.1371/journal.pone.0024691.g004
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response in ASD, our results suggest a direct link between
implicated genes in ASD and molecular pathways involved in
immune signaling.
This considerable attention to the immune response in
previous ASD research has resulted in two prevailing theories:
one suggests exogenous factor(s) stimulate neuro-inflammation
during development, while the other postulates autoimmune
activation causes ASD pathology [56,57]. However, it is equally
possible—as our results support—that the mutations described in
ASD result in aberrant signaling regulation of immune cells
during neurodevelopment. This could result in cell-autonomous
activation and/or improper response to otherwise nominal
stimuli, such as occurs in the autoinflammatory syndromes
[58]. Alternatively, as glia are increasingly implicated in normal
formation of synaptic connectivity [24]—and we have demon-
strated a significant proportion of ASD-implicated genes appear
to be glial-specific—it is possible that genomic aberrations
ultimately funnel through core signaling pathways of glial cells
to disrupt formation of neural networks independent of an
inflammatory mechanism. In support of this notion, a number of
recent reports have demonstrated that these same cytokine
signaling pathways are central to proper brain development
[59,60]. Furthermore, signaling through the NFkB pathway has
been shown to be important in synaptic plasticity independent of
an inflammatory mechanism [61].
Moreover, two of three genome-wide expression studies in
Autism brain tissue conclude that the most prominent transcrip-
tome changes are related to neuro-immune disturbances. In the
Garbett et al study, the most significant functional pathway
implicated was NFkB signaling [31]. The most comprehensive
transcriptomics study of ASD post-mortem brain to date
(Voineagu et al) concludes that one of two significant co-expression
networks is involved in immune function [32]. While our results
are only a first step in linking common molecular interaction
pathways to the underlying genetic heterogeneity of ASD, they
Figure 5. Network 2 derived from the ASD highly expressed gene set. Orange genes are those present in AutDB that are highly expressed.
doi:10.1371/journal.pone.0024691.g005
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transcriptomics, cell, and tissue level studies that further
investigation into cytokine signaling in ASD is needed.
In summary, we report the spatial and temporal expression
profile of genes implicated in Autism Spectrum Disorders, in
addition to the genetically and phenotypically related neurodevel-
Table 8. Cell-type specific protein expression of highly expressed ASD genes from the Human Protein Atlas database.
Neurons Glia Cerebellum
Cortex Hipp Lat Vent Cortex Hipp Lat Vent Purkinje Granular Molecular
FABP7 22 2 ++ +++ ++ 22 ++
GNAS 22 2 22 2 2 2 2
GPX1 ++ 2 ++ ++ ++ ++ 22
HNRNPH2 +++ +++ +++ +++ ++ ++ ++ +++ +++
HRAS +++ +++ +++ +++ +++ +++ 2 +++ +++
PDZD4 ++ + ++ + + +++ ++ 2 ++
RPL10 +++ +++ +++ +++ ++ ++ +++ ++ +++
TSPAN7 +++ ++ ++ 22 2 2 2 2
MAP2 +++ +++ +++ 22 2 +++ +++ +++
PRKCB ++ ++ ++ 22 + ++ +++ ++
MEF2C +++ +++ +++ +++ +++ +++ +++ + +++
RAPGEF4 +++ ++ 2 ++ + ++ +++ + ++
APC + + ++ ++ ++ ++ ++ ++ +++
DCX +++ + + ++ ++ ++ ++ ++ +++
RIMS3 ++ + 22 2 ++ + 2
ROBO1 ++ ++ ++ +++ ++ ++ ++ ++ ++
GLO1 ++ ++ ++ ++ ++ ++ 22 +
DLX2 +++ ++ ++ + + + ++ + 2
CNR1 ++ + + +++ +++ +++ + ++ +++
PCDH10 ++ ++ + +++ +++ +++ + ++ +++
NLGN3 ++ +++ + 22 2 +++ +++ 2
RELN ++ + 22 2 + 22
CADM1 22 2 22 2 2 +++ 2
CDH22 + 22 ++ + 2 ++ 2
Data is reported as presented in the Atlas: +++ for ‘‘strong’’ expression, ++ for ‘‘moderate,’’ + for ‘‘weak,’’ and 2 for ‘‘negative.’’ These highly expressed ASD genes were
not present in the database: Sez6l2, Gabrb3, Hsd11b1l, Hla-A, Dlx1, Adora2a, Cadps2,a n dDHCR7. Lat vent=Lateral Ventricle, Hipp=Hippocampus.
doi:10.1371/journal.pone.0024691.t008
Table 9. Correlation of AutDB genes with published transcriptome studies in ASD brain.
Garbet et al 2008 Voineagu et al 2011 Purcell et al 2001
Brain tissue studied STC STC, PFC, Cerebellum Mainly Cerebellum
# of samples 6 ASD, 6 Ctrls 29 ASD, 29 Ctrls (cortex) 11ASD,
10 Ctrl (cerebellum)
10 ASD, 23 Ctrls
Transcriptome Profiling Method U133 Plus 2.0 GeneChip (Affymetrix) Ref8 v3 Array (Illumina) Clontech Array and UniGEM V2 Array
# of genes dysregulated in ASD 130 444 30
Main findings q Immune-related genes Genes converge on immune
and synapse modules
q AMPA-type glutamate receptors
Q Genes involved in neuronal
development
Dysregulated genes in AutDB 4/130 (3%)
1 21/444 (4.7%)
2 1/31 (3.2%)
3
1SDC2, SLC9A9, DLX1, AHI1.
2CD44, CDH10, DLX1, DPP6, GABRB3, HLA-A, KCNMA1, MET, NOS2A, PRKCB1, PTGS2, SCN1A, SLC25A12, NLGN4Y, CADM1, A2BP1, AHI1, PCDH10, PDZD4, CADPS2,
SLC9A9.
3CNR1.
STC=Superior temporal cortex, PFC=Pre-frontal cortex, cere=cerebellum.
doi:10.1371/journal.pone.0024691.t009
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proportion of implicated genes are not expressed in the developing
human brain, and a significant number appear to be mainly
expressed in glial cells. Integrated gene-network analysis, gene
ontology enrichment, and canonical pathways investigation of a
subset of highly expressed ASD genes all implicate central immune
signaling pathways as common to the heterogeneous interactome of
the implicated genes. This work serves as a framework to link the
genetic findings in ASD with transcriptome, cell, and tissue level
evidence for altered immune functions in ASD patients.
Methods
Neurodevelopmental Disorder Databases
AutDB [34] and CarpeDB [62] are updated, publically download-
able databases that catalog genes implicated/associated with Autism
and Epilepsy, respectively (Table S1). SZGene [63] is a similar
searchable database, and we obtained datafiles directly from the
curators (Table S1). In all three databases, some implicated regions are
provisional loci, non-coding RNAs, pseudogenes, or otherwise not
included in the NIMH Transcriptional Atlas of Human Brain
Development and, therefore, were not considered. All genes used in
this study and how they were implicated (e.g. GWAS, functional, etc),
with corresponding references, are documented in Table S1.
NIMH Transcriptional Atlas of Human Brain Development
The NIMH Transcriptional Atlas of Human Brain Develop-
ment (www.developinghumanbrain.org) was accessed on 2/16/
2011, and the raw Gene Matrix. csv datafile was downloaded. We
re-organized the data so that rows are genes and columns are
developmental time points subdivided according to brain region.
While the Atlas contains data for 16 different brain regions, we
narrowed our focus to those 11 that were most relevant to autism
[20,41]: Dorsolateral Prefrontal Cortex (DLPC), Ventrolateral
Prefrontal Cortex (VLPC), Medial Prefrontal Cortex (MPC),
Orbital Prefrontal Cortex (OPC), Posterior Superior Temporal
Cortex (PSTC), Inferior Lateral Temporal Cortex (ILTC),
Hippocampus (Hipp), Amygdala (Amyg), Striatum (Stri), Cerebel-
lum (Cere), and Primary Motor Cortex (PMC). Genes in AutDB,
CarpeDB, and SZGene were parsed from the full database to
create disease-specific expression databases (Tables S2, S3, S4).
Our analysis only considered time points up to 23 years old.
Gene Expression Analysis
Expression values were divided into quintiles and given corre-
sponding colors for heat map creation (,20 RPKM, 20–40 RPKM,
40–60 RPKM, 60–80 RPKM, .100 RPKM). Genes were then
assigned to one of five tiers within each brain region based on their
highest level of expression across all time points, in a conservative
attempt to analyze the expression data qualitatively. For example, if a
gene is expressed at 150 RPKM at 24 weeks gestation (wg) and at 80
RPKM for all other time points, it is placed in the .100 RPKM tier.
Based on results from established housekeeping genes (see Results), we
considered a gene to be differentially expressed if it crossed more than
three tiers. Because of this, genes in the top three tiers were considered
to be ‘‘highly expressed,’’ and were the focus of our subsequent
analysis (Tables S2, S3, S4, ‘‘Highly Expressed Genes’’ tab).
Gene Ontology Enrichment Analysis
To test if a subset of genes implicated different Gene Ontology
categories than a background set of all genes, we employed the
Gene Ontology Enrichment Analysis and Visualization tool [64],
accessed at http://cbl-gorilla.cs.technion.ac.il/. We specified the
organism as Homo sapiens, chose the option for two unranked lists of
genes, and set the p-value threshold to 0.01.
Ingenuity Pathway Analysis
Integrated gene-network analysis for the AutDB, CarpeDB, and
SZGene sets and on the highly expressed subsets were generated
by Ingenuity Pathways Analysis (Version 8.8, IngenuityH Systems,
www.ingenuity.com). Each gene identifier was mapped to its
corresponding gene object in the Ingenuity Pathways Knowledge
Base. The gene lists were overlaid onto a global molecular network
developed from information contained in the Ingenuity Pathways
Knowledge Base. These focus gene networks were then algorith-
mically generated based on their connectivity.
Canonical pathways analysis identified the pathways from the
Ingenuity Pathways Analysis library of canonical pathways that
were most significant to the data set. The significance of the
association between the data set and the canonical pathway was
measured in two ways: i) A ratio of the number of molecules from
the data set that map to the pathway divided by the total number
of molecules that map to the canonical pathway and ii) Fisher’s
exact test was used to calculate a p-value determining the
probability that the association between the genes in the dataset
and the canonical pathway is explained by chance alone. A p-
value of less than 0.01 was considered significant. For comparison
analysis between all disease genes and highly expressed genes,
Benjamini-Hochberg multiple testing correction was used to
calculate p-values, with 0.01 set as a significance threshold.
Functional Network Analysis identified the biological interac-
tions that were most significant to the molecules in the network.
The network molecules associated with biological functions and/
or diseases in Ingenuity’s Knowledge Base were considered for the
analysis. Right-tailed Fisher’s exact test was used to calculate a p-
value determining the probability that each biological function
assigned to that network is due to chance alone, with a threshold of
0.01 set for significance. A graphical representation of the
molecular relationships between molecules was generated. Mole-
cules are represented as nodes, and the biological relationship
between two nodes is represented as an edge (line). All edges are
supported by at least one reference from the literature. Nodes are
displayed using various shapes that represent the functional class of
the gene product. Edges are displayed as either solid or broken
lines to describe the nature of the relationship between the nodes
(solid for direct interaction, broken for an indirect interaction).
Human Protein Atlas
To compare expression data at the transcriptome level to protein-
level expression, we accessed the Human Protein Atlas [35] at http://
www.proteinatlas.org/. The Human Protein Atlas is a publicly
available database cataloging the distribution of proteins in different
normal human tissues, cancer types, and cell lines via validated
antibody analysis. The data includes immunohistochemisty, Western
blot analysis and, for a large fraction, a protein array assay and
immunofluorescent based confocal microscopy. We utilized the
reported levels of antibody staining as given, except for genes that
contained annotated expression results, which we reported instead.
Supporting Information
Figure S1 Expression profile of the 15 most constantly
expressed genes identified by Hsiao et al.
(XLS)
Figure S2 Expression profile of 10 cannonical house-
keeping genes.
(XLS)
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mediate Filament Genes. NEFL is specific to neurons
(Neurofilament, Entrez ID 4747), GFAP is specific to Glia (Glial
Fibriallary Acidic Protein, Entrez ID 2670), VIM is specific to
mesoderm derivatives (Vimentin, Entrez ID 7431), DES is specific
to muscle (Desmin, Entrez ID 1674), and KRT1 (Keratin, Entrez
ID 3848) is specific to epithelium.
(XLS)
Figure S4 Expression profile of Cannabinoid Receptor 1
and 2.
(XLS)
Figure S5 Expression profile of the most highly ex-
pressed ASD-implicated genes.
(XLS)
Figure S6 Schematic diagram of the canonical pathway
‘‘Reelin Signaling in Neurons.’’ Genes implicated in ASD,
Epilepsy, and Schizophrenia are indicated with shading. Grey
shading indicates the gene is implicated in more than one of these
disorders, yellow is specific to Schizophrenia and Pink specific to
ASD.
(TIF)
Figure S7 Overlay of ASD interactome networks by
brain region for the 32 highly expressed genes. There was
no significant clustering of networks by brain region. Dark
blue=Amygdala, Light Blue=Motor, Turquoise=Striatum,
Black=Combined frontal, Grey=Combined temporal, Beige=
Hippocampus, Dark Red=Cerebellum.
(TIF)
Figure S8 Overlay of Schizophrenia interactome net-
works. Dark blue networks are from the highly expressed
enriched set, light blue networks from all Schizophrenia genes
analyzed. No central networks were apparent.
(TIF)
Figure S9 Overlay of Epilepsy interactome networks.
Dark blue networks are from the highly expressed enriched set,
light blue networks from all Epilepsy genes analyzed. No central
networks were apparent.
(TIF)
Table S1 Genes from AutDB, SZGene, and CarpeDB.
(XLSX)
Table S2 Expression heat map of AutDB genes.
(XLSX)
Table S3 Expression heat map of SZGene genes.
(XLSX)
Table S4 Expression heat map of CarpeDB genes.
(XLSX)
Table S5 Temporal Expression Profiles by Region for
all 32 Highly Expressed ASD genes.
(XLSX)
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